Lassa Fever (Fever, Lassa)

01/02/1986 - "In a study of Lassa fever in Sierra Leone, West Africa, we identified two variables associated with a high risk of death, and we evaluated the efficacy of ribavirin and Lassa virus-convalescent plasma for the treatment of Lassa fever. "
01/01/1991 - "[The therapeutic efficacy of ribamidil and virazole in experimental Lassa fever in monkeys]."
01/02/1986 - "We conclude that ribavirin is effective in the treatment of Lassa fever and that it should be used at any point in the illness, as well as for postexposure prophylaxis."
03/01/1990 - "[Comparative evaluation of the antiviral efficacy of virazole and ribamidil in experimental Lassa fever in monkeys]."
08/01/1984 - "Clinical studies with ribavirin in persons infected with Lassa Fever virus are in progress. "

11/01/2003 - "[Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever]."
11/01/2003 - "The use of guinea pigs as a laboratory model was proven to be appropriate in investigating the vaccines developed against Lassa fever at the preclinical study stage. "
10/01/2012 - "Currently, there are no approved vaccines against Lassa fever for use in humans. "
06/01/2005 - "Currently, there are no licensed vaccines for Lassa fever, and no experimental vaccine has completely protected nonhuman primates against a lethal challenge. "
07/01/1989 - "The protection resulting from vaccination with the recombinant virus vaccines did not correlate with the levels of prechallenge serum antibodies, suggesting that a cell-mediated immune response is a critical component of protective immunity to Lassa fever."

01/01/1985 - "The efficacy of passive immunization for treatment of Lassa Fever (LF) is believed to depend on the titre of the neutralizing antibody infused. "
05/01/1984 - "Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain."
03/01/2000 - "T cells must play the major role in controlling acute human Lassa virus infection, because patients recover from acute Lassa fever in the absence of a measurable neutralizing antibody response. "
07/01/1997 - "Specific immunoglobulin with at least 1:512 titer of virus-neutralizing antibodies to Lassa fever was obtained by alcohol sedimentation after Cohn from the blood serum of immunized horses. "
08/01/2004 - "Because arenaviruses like LCMV or Lassa fever virus (LFV) generate poor neutralizing antibodies during natural infection or vaccination, we assayed whether the alpha-DG receptoid bodies generated could be used as an efficient antibody mimic. "

07/01/1997 - "Preclinical studies of immunoglobulin to Lassa fever demonstrated its safety and a high specific activity. "
07/01/1997 - "[Development and study of properties of immunoglobulins against Lassa fever]."
03/01/1997 - "[Development and study of immunoglobulins against Lassa fever]."
07/01/1997 - "Specific immunoglobulin with at least 1:512 titer of virus-neutralizing antibodies to Lassa fever was obtained by alcohol sedimentation after Cohn from the blood serum of immunized horses. "

11/01/1998 - "Because of its high negative predictive value, a single IgM immunoblot result will be valuable for excluding acute Lassa fever for cases of FUO in areas where Lassa fever is endemic."
11/01/1998 - "The positive and negative predictive values of a single IgM immunoblot result for acute, PCR-confirmed Lassa fever were therefore 53.6 and 93.0%, respectively. "
11/01/1998 - "On admission to the hospital, nine Lassa fever patients (75%) were reactive by the IgM immunoblot assay. "
07/01/1997 - "All of the health workers with specific IgM came from a single facility in Lafia, sampled during an outbreak of Lassa fever."
10/01/2012 - "The sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at early phase of Lassa fever infection."

01/01/2010 - "To this end, we investigated the presence of sGP1 in the serum of suspected LASV patients admitted to the Kenema Government Hospital (KGH) Lassa Fever Ward (LFW), in Kenema, Sierra Leone that tested positive for viral antigen or displayed classical signs of Lassa fever. "
01/01/1986 - "Use of monoclonal antibody for the detection of Lassa virus antibody and antigen in patients with Lassa fever."
02/02/1985 - "Early diagnosis of human Lassa fever by ELISA detection of antigen and antibody."
09/01/1986 - "E6 Vero cells infected with Lassa fever virus (LAS), Rift Valley Fever virus (RVF), Congo Hemorrhagic Fever virus (CON), Marburg virus (MBG) and the Ebola (EBO) virus strains Mayinga (May) and Boniface (Bon) were used as antigen. "
02/02/1985 - "All acute-phase Lassa-fever sera contained either antigen or IgM antibody, and most contained both, thus allowing early diagnosis with single serum samples. "

04/01/2012 - "Recent studies have illuminated how the hemorrhagic fever viruses Ebola and Lassa fever prevent host sensing of double-stranded RNA (dsRNA), a key hallmark of viral infection. "

08/01/1984 - "These studies in a realistic primate model suggest that the antigen detection ELISA or the IgM capture ELISA described, in which beta-propiolactone-inactivated sera are used, should be useful for the rapid diagnosis of human Lassa fever."

08/01/1982 - "The availability of a rodent model for human Lassa fever in uniformly susceptible strain 13 guinea pigs should facilitate detailed pathophysiological studies and efficacy testing of antiviral drugs, candidate vaccines, and immunotherapy regimens to develop control methods for this life-threatening disease in humans."

12/01/1994 - "Sequential serum samples from 29 hospitalized patients confirmed to have Lassa fever were tested by RT-PCR and for Lassa virus-specific antibodies by indirect immunofluorescence (IF). "
11/01/1989 - "A few individuals had antibodies against Crimean-Congo haemorrhagic fever, Lassa, Ebola and Marburg viruses, suggesting that these viruses all circulate in the area."
01/01/1979 - "Lassa fever antibodies in hospital personnel in the Plateau State of Nigeria."
01/01/1978 - "Six persons had Lassa fever antibodies: four midwives and two students of midwifery. "
12/01/1996 - "To control for the confounding effects of differences in rodent infestation and food storage, rodent consumption was analyzed as a risk factor for transmission of Lassa virus comparing rodent consumers (RC) and nonconsumers (NC) in Gueckedou only: 14.6% of RC had Lassa virus antibodies versus 7.4% of NC (P = 0.1) and 23.0% of RC reported a history of a febrile illness with hearing loss (the most common sequel of Lassa fever) versus 6.1% of NC (P = 0.003)."

01/01/2010 - "Treatment of acute Lassa fever infections has successfully utilized intravenous administration of ribavirin, a nucleotide analogue drug, but this is not an approved use; efficacy of oral administration has not been demonstrated. "

08/01/1982 - "The availability of a rodent model for human Lassa fever in uniformly susceptible strain 13 guinea pigs should facilitate detailed pathophysiological studies and efficacy testing of antiviral drugs, candidate vaccines, and immunotherapy regimens to develop control methods for this life-threatening disease in humans."

01/01/2013 - "The highest reported incidence of Lassa fever in the world is consistently in the Kenema District of Sierra Leone, a region that was at the center of Sierra Leone's civil war in which tens of thousands of lives were lost and hundreds of thousands of dwellings destroyed. "
02/28/1998 - "Viral haemorrhagic fevers, such as Lassa fever and yellow fever, cause tens of thousands of deaths annually outside the Netherlands. "

11/30/1985 - "Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques."

02/20/2006 - "A single subcutaneous injection of the recombinant vaccine protected strain 13 guinea pigs against fatal Lassa Fever. "